Another recognition, with another opportunity to showcase the amazing work Kitea Health is doing.
Kitea Health has been nominated for the prestigious 2024 KiwiNet Research Commercialization Awards. Award Category: PwC Breakthrough Project.
The team from Kitea Health has developed a product that can proactively monitor changes in intracranial pressure for patients with hydrocephalus. While shunts are currently used to manage hydrocephalus, they have a staggering 50% failure rate. It's often unclear to patients, who are often children and their families, whether an everyday symptom such as a headache or tiredness is a shunt failure or not.
This award also highlights the company's history and journey. Starting with 15 years of research from the implantable device group within Auckland Bioengineering Institute at the University of Auckland, driven by a clinical need, Kitea Health is now a company that is making a difference. This is also an opportunity for the company to pay tribute to the supporters, employees, patients, and their family.
